Wegovy supply in the UK: what the current picture looks like

You've searched, you've waited — here's what's been happening

Picture this: you finally got a prescription for Wegovy, or you're close to it, and then you hear the pharmacy can't fulfil it. That's been the reality for a meaningful number of people in the UK, and it's understandably frustrating. The short explanation is that when a new weight-loss medicine generates significant clinical interest, manufacturing ramp-up doesn't always keep pace. Novo Nordisk publicly acknowledged supply constraints affecting Wegovy across multiple markets, and the UK was not exempt.

The picture has improved. By late 2025 and into 2026, supply had stabilised at most dose levels for most providers working through the licensed UK supply chain. That said, whether Wegovy is in short supply at any given moment depends on dose, geography and the specific pharmacy you use, so it's worth checking directly rather than assuming shortages are still blanket. Our frequently asked questions page covers some of the most common concerns people raise about this.

One genuine development worth knowing: on 14 April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, a higher maintenance dose that delivers roughly 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide results. That approval brought a new format into the UK market, which over time should ease pressure on the existing pen supply rather than compete with it. The MHRA's announcement of the 7.2mg pen approval sets out the clinical detail.

How Wegovy supply actually reaches patients in the UK

Wegovy arrives in UK pharmacies through Novo Nordisk's authorised distributor network, the same licensed wholesale chain that supplies GP practices and hospital pharmacies. This matters because it's the mechanism that keeps the medicine genuine. Pens bought outside this chain, through social media sellers or websites offering the medicine without a clinical assessment, carry serious risks: the MHRA has seized millions of doses of counterfeit weight-loss pens in the UK, some containing insulin rather than semaglutide. Report any suspect seller via the MHRA's Yellow Card scheme, which also accepts reports of suspected side effects.

Legitimate private pharmacies source stock through this wholesale chain and are accountable to the GPhC. If a provider can't tell you their GPhC registration number or directs you to buy in a way that bypasses a prescription, that's a red flag worth taking seriously. You can verify any pharmacy on the GPhC pharmacy register in seconds. At nume, our GPhC premises registration is 9012878, verifiable directly on that register.

Supply questions also intersect with the question of quantity. Some patients ask about a one-month supply to start; others, once established on a stable dose, prefer to look at a three-month supply for convenience. What's available at any given time is confirmed at the point of clinical review, not before, because the prescriber's assessment of which dose is right for you shapes what needs to be dispensed.

NHS supply vs private supply: the practical difference

NHS Wegovy supply flows through specialist weight management services under NICE guidance (TA875), which recommends semaglutide for up to two years within a multidisciplinary specialist service, for adults with a BMI of 35 or above and at least one weight-related condition. Those thresholds are 2.5 kg/m² lower for some ethnic backgrounds under UK guidance. Waiting lists within NHS specialist services are substantial in many areas, and not every area has fully commissioned access yet.

Private supply operates differently. A regulated online pharmacy can prescribe and dispense Wegovy to eligible adults (BMI 30 or above, or 27 or above with a qualifying weight-related condition) following a clinical assessment, without a referral or a waiting list. Speed and continuity of supply are usually better through the private route, though cost is the patient's responsibility. For context on what private treatment involves financially, our cost and pricing guide for Wegovy in the UK is worth reading. The question of who supplies Wegovy legitimately in the UK has its own dedicated page if you want to go deeper on the supply chain.

For a broader look at semaglutide as a medicine (how it works, what the clinical evidence says and how it compares to other options) the semaglutide overview is a good place to start, and the Wegovy treatment page covers the UK-specific detail including the newer 7.2mg dose. NHS England's guidance on weight-management injections sets out the NHS access criteria and wraparound care requirements clearly.

Checking your eligibility and confirming what's available for you

Supply questions and eligibility questions tend to arrive together, and they're connected. If you haven't yet had a clinical assessment, there's little point trying to navigate stock levels for doses that may not be appropriate for your starting point. The licensed titration schedule for Wegovy begins at 0.25mg, moving up through 0.5mg, 1.0mg, 1.7mg and 2.4mg (or now to 7.2mg at the prescriber's direction) with roughly four weeks at each level. What matters first is whether Wegovy is the right treatment for you, not which dose is in stock today.

Our prescribers review every consultation personally. A real clinician looks at your answers, your health history and your goals, not a scoring algorithm. Once approved, treatment is dispatched the same day for orders placed before midday Monday to Friday, arriving free the next working day by tracked DPD courier. If you've had supply problems elsewhere or you're coming from another provider, our support team can talk through transfer options before you commit.

If you're ready to find out whether Wegovy is clinically suitable for you and what's currently available at your dose level, the right next step is a consultation with a registered prescriber. Start your free consultation with a clinician at nume's GPhC-registered pharmacy.